Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm
- PMID: 35835341
- DOI: 10.1016/j.bbcan.2022.188759
Predicting cancer evolution for patient benefit: Renal cell carcinoma paradigm
Abstract
Evolutionary features of cancer have important clinical implications, but their evaluation in the clinic is currently limited. Here, we review current approaches to reconstruct tumour subclonal structure and discuss tumour sampling method and experimental design influence. We describe clear-cell renal cell carcinoma (ccRCC) as an exemplar for understanding and predicting cancer evolutionary dynamics. Finally, we discuss how understanding cancer evolution can benefit patients.
Keywords: Cancer dynamics; Cancer evolution; Clear cell renal cell carcinoma; Patient benefit; Patient management; Representative sequencing; Subclonal reconstruction.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Samra Turajlic reports financial support was provided by Cancer Research UK. Samra Turajlic reports financial support was provided by The Royal Marsden Cancer Charity. Samra Turajlic reports financial support was provided by The Rosetrees Trust. Samra Turajlic reports financial support was provided by Ventana Medical Systems Inc. Samra Turajlic reports financial support was provided by National Institutes of Health. Samra Turajlic reports financial support was provided by Melanoma Research Alliance. Samra Turajlic reports a relationship with Roche that includes: speaking and lecture fees. Samra Turajlic reports a relationship with Astra Zeneca that includes: speaking and lecture fees. Samra Turajlic reports a relationship with Novartis that includes: speaking and lecture fees. Samra Turajlic reports a relationship with Ipsen that includes: speaking and lecture fees. Samra Turajlic has patent 'Indel mutations as a therapeutic target and predictive biomarker' (PCTGB2018/051892) and (PCTGB2018/051893) pending to EPO. Samra Turajlic has patent 'Clear Cell Renal Cell Carcinoma Biomarkers' (P113326GB) pending to EPO.
Similar articles
-
Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma.J Biomed Sci. 2025 Feb 8;32(1):17. doi: 10.1186/s12929-024-01111-9. J Biomed Sci. 2025. PMID: 39920694 Free PMC article. Review.
-
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.Cell. 2018 Apr 19;173(3):595-610.e11. doi: 10.1016/j.cell.2018.03.043. Epub 2018 Apr 12. Cell. 2018. PMID: 29656894 Free PMC article.
-
Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.Eur Urol Focus. 2021 Jan;7(1):152-162. doi: 10.1016/j.euf.2019.06.009. Epub 2019 Jun 29. Eur Urol Focus. 2021. PMID: 31266731
-
Multiple metastatic clones assessed by an integrative multiomics strategy in clear cell renal carcinoma: a case study.J Clin Pathol. 2022 Jun;75(6):426-430. doi: 10.1136/jclinpath-2020-207326. Epub 2021 Mar 25. J Clin Pathol. 2022. PMID: 33766955
-
Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?Histopathology. 2019 Jan;74(1):60-67. doi: 10.1111/his.13749. Histopathology. 2019. PMID: 30565303 Review.
Cited by
-
Clear Cell Renal Cell Carcinoma: A Test Bench for Investigating Tumor Complexity.Cancers (Basel). 2024 Feb 19;16(4):829. doi: 10.3390/cancers16040829. Cancers (Basel). 2024. PMID: 38398220 Free PMC article.
-
Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma.J Biomed Sci. 2025 Feb 8;32(1):17. doi: 10.1186/s12929-024-01111-9. J Biomed Sci. 2025. PMID: 39920694 Free PMC article. Review.
-
Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study.Cancer Rep (Hoboken). 2024 Jun;7(6):e2116. doi: 10.1002/cnr2.2116. Cancer Rep (Hoboken). 2024. PMID: 38837683 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
